News

Public · Published

Axsome Therapeutics Price Target Cut to $273.00/Share From $295.00 by RBC Capital

RBC Capital lowered its price target for Axsome Therapeutics shares to $273.00 from $295.00, while keeping an Outperform rating on the stock, according to a ratings action report.

Published:

Updated:

What happened

RBC Capital lowered its price target for Axsome Therapeutics shares to $273.00 from $295.00, while keeping an Outperform rating on the stock, according to a ratings action report.

Confirmed

Global impact / market context

A lower price target signals that RBC still expects the stock to rise but now expects a smaller gain than before. That can shape how investors view the company's prospects and whether they choose to buy or hold the shares.

Analyst inference

Analyst rating changes often draw attention from investors who use them as one input when deciding how to position their money. A target cut with an unchanged Outperform rating suggests the analyst remains positive on the stock overall.

Analyst inference

What to watch

  1. RBC Capital kept its Outperform rating on Axsome Therapeutics even as it cut the price target, so the rating itself was not downgraded in this action. Confirmed
  2. Watch whether other analysts revise their own price targets or ratings for Axsome Therapeutics, since changes can signal shifting views on the company's outlook. Proposed
  3. Track Axsome Therapeutics' future company updates, since new information about its business could prompt further analyst price target changes over time. Analyst inference

Evidence

  • Original source link unavailable